| Title | Drug Insight: safety of intravenous iron supplementation with sodium ferric gluconate complex. | | Author(s) | Michael B, Fishbane S, Coyne DW, Agarwal R, Warnock DG | | Institution | B Michael is Clinical Associate Professor of Medicine at Thomas Jefferson University, Philadelphia, PA, S Fishbane is Chief of the Nephrology Section at Winthrop University Hospital, Mineola, New York, NY, DW Coyne is Professor of Medicine at Washington University School of Medicine, St. Louis, MO, R Agarwal is Associate Professor of Medicine at Indiana University School of Medicine, Indianapolis, IN and DG Warnock is Director of Nephrology at the University of Alabama at Birmingham, Birmingham, AL, USA. | | Source | Nat Clin Pract Nephrol 2006 Feb; 2(2):92-100. | | Abstract | Intravenous iron is necessary for optimal management of anemia in patients receiving hemodialysis and is utilized in the majority of these patients in the US. The availability of nondextran formulations of intravenous iron has significantly improved the safety of its use. The nondextran iron formulation sodium ferric gluconate complex (SFGC) has been extensively studied in the hemodialysis population, with two large phase IV trials documenting its safety. SFGC is efficacious and, at recommended doses, is associated with a low incidence of adverse events. There have been few comparative studies of the nondextran intravenous iron preparations; however, they are known to have different pharmacokinetic characteristics. There is also evidence to indicate that these compounds differ in terms of their cytotoxic and proinflammatory properties, and their propensity to induce oxidative stress. This paper reviews the current literature on the safety of SFGC and examines the emerging safety issues surrounding the use of intravenous iron. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 16932400 |
|
